Loading...
Market
Which major country will approve mRESVIA RSV Vaccine first after Canada by Dec 31, 2025?
2
Resolution / Starting Odds
United States • 25%
United Kingdom • 25%
Australia • 25%
Other • 25%
Official announcements from respective national health agencies
Story
Moderna's mRESVIA RSV Vaccine Approved by Health Canada for Adults 60 and Older
Nov 8, 2024, 03:13 PM
Moderna has received approval from Health Canada for its respiratory syncytial virus (RSV) vaccine, mRESVIA, for adults aged 60 years and older. This marks the first mRNA-based vaccine for RSV to be authorized in Canada. The approval was announced on Friday, making it a significant milestone for the vaccine maker. The stock ticker for Moderna is $MRNA.
View original story
Similar markets
European Union • 25%
Canada • 25%
Japan • 25%
Australia • 25%
USA • 25%
EU • 25%
Canada • 25%
Other • 25%
Canada • 25%
United Kingdom • 25%
Australia • 25%
Other • 25%
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
European Union • 25%
Japan • 25%
Canada • 25%
Other • 25%
Johnson & Johnson • 25%
AstraZeneca • 25%
Sanofi • 25%
Other • 25%
United States • 25%
United Kingdom • 25%
Canada • 25%
Australia • 25%
USA • 25%
Finland • 25%
Japan • 25%
Other EU country • 25%
United States • 25%
European Union • 25%
Africa • 25%
Other • 25%
United States • 25%
United Kingdom • 25%
European Union • 25%
Other • 25%
United States • 25%
United Kingdom • 25%
Germany • 25%
Other • 25%
European Union • 25%
Canada • 25%
Japan • 25%
Other • 25%